Table 2 Association of expression of PD-L1 to clinicopathological characteristics in 261 patients of lung adenocarcinoma
From: Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression
| Â | PD-L1 TPS (%) | p value | |||
|---|---|---|---|---|---|
< 1% | 1–49% | > = 50% | |||
Sex | Male (n = 131) | 75 (57.3) | 24 (18.3) | 32 (24.4) | 0.92 |
Female(n = 130) | 72 (55.4) | 27 (20.8) | 31 (23.8) |  | |
Clinical stage | I-II (n = 117) | 74 (50.3) | 23 (45.1) | 20 (31.7) | 0.04 |
III + IV (n = 144) | 73 (49.7) | 28 (54.9) | 43 (68.3) |  | |
LAC predominant components | Acinar | 57 (38.8) | 15 (29.4) | 18 (28.6) | < 0.01 |
Lepidic | 10 (6.8) | 3 (5.9) | 1 (1.6) | Â | |
Microp | 11 (7.5) | 4 (7.8) | 7 (11.1) | Â | |
Mucinous | 10 (6.8) | 0 (0) | 0 (0) | Â | |
Papillary | 39 (26.5) | 16 (31.4) | 11 (17.5) | Â | |
Solid | 20 (13.6) | 13 (25.5) | 26 (41.3) | Â | |
LACs | With uniform component (n = 114) | 71 (48.3) | 21 (41.2) | 22 (34.9) | 0.04* |
With two components (n = 104) | 53 (36.1) | 17 (33.3) | 34 (54) |  | |
With > two components (n = 43) | 23 (15.6) | 13 (25.5) | 7 (11.1) |  | |
EGFR status | Mutated (n = 154) | 84 (57.1) | 30 (58.8) | 40 (63.5) | 0.7 |
Wild-typed (n = 107) | 63 (42.9) | 21 (41.2) | 23 (36.5) |  | |